Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Mylan NV Ord Shs (MYL)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 14,802,606
  • Shares Outstanding, K 515,950
  • Annual Sales, $ 11,434 M
  • Annual Income, $ 352,500 K
  • 60-Month Beta 1.47
  • Price/Sales 1.32
  • Price/Cash Flow 3.37
  • Price/Book 1.22

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 16 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/19
See More
  • Average Estimate 0.88
  • Number of Estimates 7
  • High Estimate 1.06
  • Low Estimate 0.76
  • Prior Year 0.96
  • Growth Rate Est. (year over year) -8.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
26.00 +10.35%
on 02/27/19
31.75 -9.64%
on 02/25/19
-2.57 (-8.22%)
since 02/22/19
3-Month
26.00 +10.35%
on 02/27/19
32.23 -10.98%
on 02/20/19
+2.23 (+8.43%)
since 12/21/18
52-Week
26.00 +10.35%
on 02/27/19
42.50 -32.49%
on 06/13/18
-11.18 (-28.04%)
since 03/22/18

Most Recent Stories

More News
Glaxo Presents Encouraging Data on Endometrial Cancer Drug

Glaxo (GSK) presents encouraging data from phase I/II study on endometrial cancer drug, dostarlimab.

MYL : 28.69 (-1.91%)
MRK : 82.29 (-0.80%)
GSK : 41.25 (+0.02%)
PFE : 41.85 (-1.18%)
After Yesterday's Rally of 1.63% Shares Could Potentially Pullback

Mylan Nv (NASDAQ:MYL) traded in a range yesterday that spanned from a low of $27.93 to a high of $28.74. Yesterday, the shares gained 1.6%, which took the trading range above the 3-day high of $28.55...

MYL : 28.69 (-1.91%)
Watch for Mylan Nv to Potentially Pullback After Gaining 1.63% Yesterday

Mylan Nv (NASDAQ:MYL) traded in a range yesterday that spanned from a low of $27.93 to a high of $28.74. Yesterday, the shares gained 1.6%, which took the trading range above the 3-day high of $28.55...

MYL : 28.69 (-1.91%)
Mylan Institutional LLC Initiates Voluntary Nationwide Recall of Levoleucovorin Injection Due to the Presence of Particulate Matter

Mylan Institutional LLC is conducting a voluntary nationwide recall of two lots (see table below) of Levoleucovorin Injection, 250 mg/25 mL tothe consumer/user level. The lots were manufactured by Alidac...

MYL : 28.69 (-1.91%)
Mapi Pharma Receives Government of Israel Funding for the Establishment of a Finished Dosage Form Facility for the Manufacturing of GA Depot Pharmaceuticals

Mapi Pharma Ltd., a fully integrated, clinical, late stage biopharmaceutical company, announced today that it has received complementary funding from the Israeli Ministry of the Economy to build a new...

MYL : 28.69 (-1.91%)
MAPI : N/A (unch)
Mylan Nv is Among the Companies in the Pharmaceuticals Industry with the Best Relative Performance (MYL , OMER , PCRX , HZNP , LCI )

Below are the top five companies in the Pharmaceuticals industry as measured by relative performance. This analysis was compiled based on yesterday's trading activity as we search for stocks that have...

MYL : 28.69 (-1.91%)
PCRX : 38.22 (-3.85%)
OMER : 16.89 (-4.68%)
Insys Plunges on Auditor's Concern About Insufficient Funds

Insys Therapeutics' (INSY) shares plunge after its auditor raises concerns related to insufficiency of funds to continue operations.

MYL : 28.69 (-1.91%)
ENDP : 8.33 (-4.91%)
INSY : 4.41 (-8.32%)
TEVA : 16.33 (-4.39%)
Mylan Nv Set to Possibly Pullback After Yesterday's Rally of 1.33%

Mylan Nv (NASDAQ:MYL) traded in a range yesterday that spanned from a low of $27.35 to a high of $27.59. Yesterday, the shares gained 1.3%, which took the trading range above the 3-day high of $27.32...

MYL : 28.69 (-1.91%)
SBP, Mylan Present Keys to Hurricane Maria Survivor in Welcome Home Party -- Courtesy of $1M Pledge from the Mylan Charitable Foundation

A small crowd of SBP staff, AmeriCorps members, Puerto Rico Central Office of Recovery and Reconstruction's Omar J. Marrero, Esq and volunteers from global pharmaceutical company Mylan (NASDAQ: MYL) gathered...

MYL : 28.69 (-1.91%)
New Research: Key Drivers of Growth for Toll Brothers, Mylan N.V, Eldorado Resorts, Sinclair Broadcast Group, Eldorado Gold, and Pegasystems -- Factors of Influence, Major Initiatives and Sustained Production

In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Toll Brothers Inc. (NYSE:TOL),...

TOL : 35.46 (-0.78%)
MYL : 28.69 (-1.91%)
SBGI : 37.80 (-2.07%)
PEGA : 63.74 (-2.43%)
EGO : 4.62 (+1.54%)
ERI : 49.66 (-0.82%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 16% Sell with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum. Long term indicators fully support a continuation of the trend.

See More Share

Trade MYL with:

Business Summary

Mylan NV is a pharmaceutical company. The company develops, licenses, manufactures, markets and distributes generic and specialty pharmaceuticals. It operates primarily in the United States, Canada, Europe, the Middle East, Africa, India, Australia, Japan and New Zealand. Mylan NV, formerly known as...

See More

Key Turning Points

2nd Resistance Point 29.51
1st Resistance Point 29.10
Last Price 28.69
1st Support Level 28.30
2nd Support Level 27.91

See More

52-Week High 42.50
Fibonacci 61.8% 36.20
Fibonacci 50% 34.25
Fibonacci 38.2% 32.30
Last Price 28.69
52-Week Low 26.00

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar